Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-03-22
2011-03-22
Wen, Sharon (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100
Reexamination Certificate
active
07910107
ABSTRACT:
The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.
REFERENCES:
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5951974 (1999-09-01), Gilbert et al.
patent: 6030613 (2000-02-01), Blumberg et al.
patent: 6096506 (2000-08-01), Lee et al.
patent: 6102035 (2000-08-01), Asking et al.
patent: 6102454 (2000-08-01), Weyerstall
patent: 6407213 (2002-06-01), Carter et al.
patent: 6465239 (2002-10-01), Lee et al.
patent: 6607884 (2003-08-01), Lee et al.
patent: 6673534 (2004-01-01), Lee et al.
patent: 6891082 (2005-05-01), Lee et al.
patent: 7192717 (2007-03-01), Hill et al.
patent: 7261893 (2007-08-01), Veldman et al.
patent: 7320789 (2008-01-01), Aghajanian et al.
patent: 7381528 (2008-06-01), Lee et al.
patent: 7393682 (2008-07-01), Lee et al.
patent: 2002/0127234 (2002-09-01), El Halawani et al.
patent: 2002/0157125 (2002-10-01), Lee et al.
patent: 2003/0074680 (2003-04-01), Lee et al.
patent: 2003/0118592 (2003-06-01), Ledbetter et al.
patent: 2003/0133939 (2003-07-01), Ledbetter et al.
patent: 2003/0138422 (2003-07-01), Aghajanian et al.
patent: 2004/0055027 (2004-03-01), Lee et al.
patent: 2004/0058445 (2004-03-01), Ledbetter et al.
patent: 2004/0142382 (2004-07-01), Veldman et al.
patent: 2005/0014733 (2005-01-01), Whittemore et al.
patent: 2005/0136049 (2005-06-01), Ledbetter et al.
patent: 2005/0175614 (2005-08-01), Ledbetter et al.
patent: 2005/0180970 (2005-08-01), Ledbetter et al.
patent: 2005/0186216 (2005-08-01), Ledbetter et al.
patent: 2005/0202012 (2005-09-01), Ledbetter et al.
patent: 2005/0202023 (2005-09-01), Ledbetter et al.
patent: 2005/0202028 (2005-09-01), Ledbetter et al.
patent: 2005/0202534 (2005-09-01), Ledbetter et al.
patent: 2005/0238646 (2005-10-01), Ledbetter et al.
patent: 2005/0257278 (2005-11-01), Lee et al.
patent: 2006/0240487 (2006-10-01), Nowak et al.
patent: 2006/0240488 (2006-10-01), Nowak et al.
patent: 2008/0178310 (2008-07-01), Lee et al.
patent: 2008/0213426 (2008-09-01), Lee et al.
patent: 1411064 (2004-04-01), None
patent: WO 94/21681 (1994-09-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 96/34015 (1996-10-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 97/10847 (1997-03-01), None
patent: WO 98/33887 (1998-08-01), None
patent: WO 99/02667 (1999-01-01), None
patent: WO 99/06559 (1999-02-01), None
patent: WO 99/24618 (1999-05-01), None
patent: WO 99/40181 (1999-08-01), None
patent: WO 00/43781 (2000-07-01), None
patent: WO 01/05820 (2001-01-01), None
patent: WO 03/072714 (2003-09-01), None
patent: WO 03/072715 (2003-09-01), None
patent: WO 2004/037861 (2004-05-01), None
patent: WO 2004/039948 (2004-05-01), None
patent: WO 2004/108157 (2004-12-01), None
patent: WO 2006/102574 (2006-09-01), None
patent: WO 2006/107611 (2006-10-01), None
The Merck Manuals Online Medical Library, [online]. Whitehouse Station, NJ: Merck Research Laboratories, 2006-2007. [retrieved on Mar. 22, 2010]. Retrieved from the Internet: < URL: http://www.merck.com/mmpe/print/sec15/ch199/ch199b.html>. Anorexia Nervosa: East Disorders Shock. see pp. 1-4.
Rudikoff et al. Proc Natl Acad Sci USA 1982 vol. 79 p. 1979.
MacCallum et al. J. Mol. Biol. (1996) 262, 732-745.
Pascalis et al. The Journal of Immunology (2002) 169, 3076-3084.
Casset et al. BBRC 2003, 307:198-205.
Vajdos et al. J. Mol. Biol. (2002) 320, 415-428.
Chen et al. J. Mol. Bio. (1999) 293, 865-881.
Wu et al. J. Mol. Biol. (1999) 294, 151-162.
Padlan et al. PNAS 1989, 86:5938-5942.
Lamminmaki et al. JBC 2001, 276:36687-36694.
Al-Lazikani et al. (1997) “Standard Conformations for the Canonical Structures of Immunoglobulins,”J. Mol. Biol.273:927-48.
Alfarano et al. (2005) “The Biomolecular Interaction Network Database and related tools 2005 update,”Nuc. Acids Res.Database Issue 33:D418-24.
Attwood (2000) “Genomics: The Babel of Bioinformatics,”Science290:471-473.
Azzouz et al. (2004) “VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model,”Nature429:413-17.
Bellinge et al. (2005) “Myostatin and Its Implications on animal breeding: a review,”Animal Genetics36:1-6.
Bendig Methods: A Companion to Methods in Enzymology 8:83-93 (1995).
Bogdanovich et al. (2002) “Functional improvement of dystrophic muscle by myostatin blockade,”Nature420:418-21.
Brown et al. (1999) “Physicochemical Activation of Recombinant Latent Transforming Growth Factor-beta's 1, 2, and 3,”Growth Factors3:35-43.
Bruijn et al. (2004) “Unraveling the Mechanisms Involved in Motor Neuron Degeneration in ALS,”Annu. Rev. Neurosci.27:723-49.
Casas et al. (1998) “Association of the Muscle Hypertrophy Locus with Carcass Traits in Beef Cattle,”J. Anim. Sci.76:468-473.
Chao (2003) “Retrograde Transport Redux”Neuron39:1-2.
Clement et al. (2003) “Wild-Type Nonneuronal Cells Extend Survival of SOD1 Mutant Motor Neurons in ALS Mice,”Science302:113-17.
Davis et al. (2005) “Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase,”Proc. Natl. Acad. Sci. USA102:5981-86.
Dennler et al. (1998) “Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene,”EMBO J.17:3091-3100.
Dickman, Steven (1997) “Gene Mutation Provides More Meat on the Hoof,”Science277:1922-1923.
Dobrowolny et al. (2005) “Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model,”J. Cell Biol.168:193-99.
Downer, J. (2002) “New, Better Rat Model Reveals Astrocyte Role in ALS,”UniSci(3 pgs.) Jan. 30, 2002 http://www.unisci.com/stories/20021/0130021.htm printed Nov. 19, 2007.
Dunlop et al. (2003) “Impaired Spinal Cord Glutamate Transport Capacity and Reduced Sensitivity to Riluzole in a Transgenic Superoxide Dismutase Mutant Rat Model of Amyotrophic Lateral Sclerosis,”J. Neurosci.23:1688-96.
Dupuis et al. (2004) “Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: Benefit of a high-energy diet in a transgenic mouse model,”Proc. Natl. Acad. Sci. U.S.A.101:11159-64.
Fischer et al. (2004) “Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man,”Exp. Neurol.185:232-40.
Frev et al. (2000) “Early and Selective Loss of Neuromuscular Synapse Subtypes with Low Sprouting Competence in Motoneuron Diseases,”J. Neurosci.20:2534-42.
Gamer et al. (1999) “A Novel BMP Expressed in Developing Mouse Limb, Spinal Cord, and Tail Bud Is a Potent Mesoderm Inducer in Xenopus Embryos,”Dev. Biol.208:222-32.
Gardlik et al. (2005) “Vectors and delivery systems in gene therapy,”Med. Sci. Monit.11:RA110-21.
Gonzalez-Cadavid et al. (1998) “Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting,”Proc. Natl. Acad. Sci. U.S.A.95:14938-43.
Grobet et al. (1997) “A Deletion in the Bovine Myostatin Gene Causes the Double-Muscled Phenotype in Cattle,”Nature Genetics17:71-74.
Guo et al. (2003) “Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice,”Hum. Mol. Genet.12:2519-32.
Halpin and Harbury (2004) “DNA Display II. Genetic Manipula
Holzbaur-Howland Erika L. F.
Howland David S.
Karim Riyez
Kelley Pamela
Kelley, legal representative William
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
The Trustees of the University of Pennsylvania
Wen Sharon
Wyeth LLC
LandOfFree
Antagonist antibodies against GDF-8 and uses in treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonist antibodies against GDF-8 and uses in treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonist antibodies against GDF-8 and uses in treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2761270